1. Home
  2. PCF vs IVA Comparison

PCF vs IVA Comparison

Compare PCF & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCF
  • IVA
  • Stock Information
  • Founded
  • PCF 1987
  • IVA 2011
  • Country
  • PCF United States
  • IVA France
  • Employees
  • PCF N/A
  • IVA N/A
  • Industry
  • PCF Trusts Except Educational Religious and Charitable
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCF Finance
  • IVA Health Care
  • Exchange
  • PCF Nasdaq
  • IVA Nasdaq
  • Market Cap
  • PCF 196.9M
  • IVA 162.8M
  • IPO Year
  • PCF N/A
  • IVA 2020
  • Fundamental
  • Price
  • PCF $6.62
  • IVA $2.94
  • Analyst Decision
  • PCF
  • IVA Strong Buy
  • Analyst Count
  • PCF 0
  • IVA 4
  • Target Price
  • PCF N/A
  • IVA $13.25
  • AVG Volume (30 Days)
  • PCF 74.8K
  • IVA 7.6K
  • Earning Date
  • PCF 01-01-0001
  • IVA 03-26-2025
  • Dividend Yield
  • PCF 10.90%
  • IVA N/A
  • EPS Growth
  • PCF N/A
  • IVA N/A
  • EPS
  • PCF N/A
  • IVA N/A
  • Revenue
  • PCF N/A
  • IVA $15,243,814.00
  • Revenue This Year
  • PCF N/A
  • IVA $18.05
  • Revenue Next Year
  • PCF N/A
  • IVA $46.74
  • P/E Ratio
  • PCF N/A
  • IVA N/A
  • Revenue Growth
  • PCF N/A
  • IVA N/A
  • 52 Week Low
  • PCF $5.71
  • IVA $1.53
  • 52 Week High
  • PCF $6.96
  • IVA $3.98
  • Technical
  • Relative Strength Index (RSI)
  • PCF 43.49
  • IVA 52.48
  • Support Level
  • PCF $6.56
  • IVA $2.88
  • Resistance Level
  • PCF $6.68
  • IVA $3.10
  • Average True Range (ATR)
  • PCF 0.07
  • IVA 0.18
  • MACD
  • PCF -0.00
  • IVA -0.02
  • Stochastic Oscillator
  • PCF 41.67
  • IVA 54.55

About PCF High Income Securities Fund

High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: